OBJECTIVES

To provide updated review on prognostic factor which in relation to overall survival (OS), progression free survival (PFS), or disease free survival (DFS) in TNBC patients.

METHODS

We conduct a systematic search as per GRADE checklist using electronic database through PUBMED and EMBASE for both full publications and congress abstracts up to 1^st February 2020. Two researchers performed these searches in parallel and made validation. Manual search and cross-referencing were performed. Studies that performed multivariate analysis on overall survival or progression-free survival of TNBC patients were included in this review.

RESULTS

Only 32 out of 1,256 studies (5,228 patients) was included, and 32 GE were most evaluated on clinical outcome based on number of publication (N) or patients participated (P) were Ki67 (N=9, P=1,630), p53 (N=7,P=1,436), PD-L1 (N=4,P=839) respectively, whereas Ki67, p53 or PDL- had most reported on survival. The ALDH1, Aur-A, B-catenin, E-cadhelin, BCL2 and FOXC-1 were reported in lesser extent and sample size. Early setting was reported in 31 studies (96.7%), and 18 studies (56%) were conduct in Asia Pacific regions. 13 (40.6%) studies report in both OS and PFS, 14 studies report in PFS or DFS and 5 studies report in OS. Although there were a heterogeneous type of prognostic factors that affected clinical outcome of TNBC, only a few have statistical significance related.

CONCLUSIONS

The prognostic factors worsen clinical outcome in TNBC were Ki67, p53 and PD-L1. To quantify its impact on clinical outcome using pooled data should explored further including another of mutation GE.